Judge to weigh if Texas AG can block Kenvue dividend over Tylenol

A Texas judge will hear Attorney General Ken Paxton's bid to block Kenvue (KVUE.N) from paying a $398 million dividend and marketing Tylenol as safe for pregnant women, alleging the drug causes autism and ADHD. Paxton's lawsuit, which also targets former parent Johnson & Johnson (JNJ.N), claims Kenvue must conserve cash due to potential multi-billion dollar liabilities from Tylenol and talc cases, creating a significant overhang for Kimberly-Clark's (KMB.O) planned $40 billion acquisition of Kenvue. Kenvue and J&J vehemently defend Tylenol's safety, citing medical consensus and arguing Paxton's politically motivated claims lack jurisdiction and would constitute an illegal intervention in corporate governance.

Analysis

A Texas judge is set to consider Attorney General Ken Paxton's motion to block Kenvue (KVUE) from distributing a $398 million dividend and marketing Tylenol as safe for pregnant women. Paxton's lawsuit, filed October 28, alleges Tylenol use during pregnancy causes autism and ADHD, and claims Kenvue must conserve cash due to potential multi-billion dollar liabilities from Tylenol and talc litigation. This legal action introduces significant uncertainty around Kenvue's capital returns and operational autonomy.

The lawsuit poses a material overhang on Kimberly-Clark's (KMB) proposed $40 billion acquisition of Kenvue, announced six days after Paxton's initial filing. KMB's strategic rationale for the acquisition, aimed at expanding into higher-margin categories, could be jeopardized by increased legal and regulatory scrutiny surrounding Kenvue's product portfolio. The general sentiment for KVUE, JNJ, and KMB is moderately negative, reflecting this uncertainty.

Kenvue and Johnson & Johnson (JNJ) vehemently defend Tylenol's safety, citing medical consensus and arguing the lawsuit is politically motivated and lacks jurisdiction. They contend that blocking the dividend would constitute an illegal intervention in corporate governance and that Kenvue is not insolvent. The U.S. FDA's September directive for doctors to alert patients to growing evidence linking Tylenol to autism, despite medical societies disputing the link, adds complexity to the legal and public perception landscape.

Key Decisions for Investors

• Investors should closely monitor the outcome of the November 14 court hearing, as an injunction could directly impact Kenvue's capital allocation strategy and the viability of Kimberly-Clark's acquisition.
• Evaluate the potential for increased litigation risk and contingent liabilities for both Kenvue and Johnson & Johnson, considering the ongoing legal challenges and conflicting scientific opinions regarding Tylenol's safety.
• Assess Kimberly-Clark's strategic rationale for the Kenvue acquisition against heightened regulatory and legal scrutiny, which could lead to revised deal terms, delays, or even termination.